 |
Overview |
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines.
Our first product candidate Vvax001, an immunotherapy against (pre)malignant cervical lesions, has succesfully completed Phase II clinical development and is preparing for Phase III clinical trial aimed to obtain market authorization.
Cervical cancer is the second largest cause of cancer deaths in women worldwide. There is a clear, currently unmet, need for an effective therapeutic vaccine for patients with premalignant cervical lesions, so called CIN2/3.
Prophylactic Human Papillomavirus (HPV) vaccines will not affect this need for decades to come. Therapeutic vaccinations offers an attractive alternative to the current surgical options for treating premalignant lesions; it can address the underlying viral HPV infection as well as all HPV-associated lesions regardless of location, and induce long-lasting immunity, thus preventing recurrence. |
| |
|
|
